Institution
Peking Union Medical College Hospital
Healthcare•Beijing, China•
About: Peking Union Medical College Hospital is a healthcare organization based out in Beijing, China. It is known for research contribution in the topics: Medicine & Population. The organization has 15996 authors who have published 16018 publications receiving 226505 citations.
Topics: Medicine, Population, Cancer, Lung cancer, Internal medicine
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics, as well as potential biomarkers for predicting disease severity in 2019-nCoV-infected patients in Shenzhen, China, suggest a number of potential diagnosis biomarkers and angiotensin receptor blocker drugs for potential repurposing treatment of 2019- nCoV infection.
Abstract: The outbreak of the 2019-nCoV infection began in December 2019 in Wuhan, Hubei province, and rapidly spread to many provinces in China as well as other countries. Here we report the epidemiological, clinical, laboratory, and radiological characteristics, as well as potential biomarkers for predicting disease severity in 2019-nCoV-infected patients in Shenzhen, China. All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS). The most common laboratory abnormalities were hypoalbuminemia, lymphopenia, decreased percentage of lymphocytes (LYM) and neutrophils (NEU), elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH), and decreased CD8 count. The viral load of 2019-nCoV detected from patient respiratory tracts was positively linked to lung disease severity. ALB, LYM, LYM (%), LDH, NEU (%), and CRP were highly correlated to the acute lung injury. Age, viral load, lung injury score, and blood biochemistry indexes, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%), may be predictors of disease severity. Moreover, the Angiotensin II level in the plasma sample from 2019-nCoV infected patients was markedly elevated and linearly associated to viral load and lung injury. Our results suggest a number of potential diagnosis biomarkers and angiotensin receptor blocker (ARB) drugs for potential repurposing treatment of 2019-nCoV infection.
1,541 citations
••
Guangzhou Medical University1, Huazhong University of Science and Technology2, Southern Medical University3, Southern University of Science and Technology4, Sun Yat-sen University5, The Chinese University of Hong Kong6, Peking Union Medical College Hospital7, Zhejiang University8, Chinese Center for Disease Control and Prevention9, Li Ka Shing Faculty of Medicine, University of Hong Kong10, Wuhan University of Science and Technology11, Hubei University of Medicine12
TL;DR: The 2019-nCoV epidemic spreads rapidly by human-to-human transmission and the disease severity (including oxygen saturation, respiratory rate, blood leukocyte/lymphocyte count and chest X-ray/CT manifestations) predict poor clinical outcomes.
Abstract: Background Since December 2019, acute respiratory disease (ARD) due to 2019 novel coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. We sought to delineate the clinical characteristics of these cases. Methods We extracted the data on 1,099 patients with laboratory-confirmed 2019-nCoV ARD from 552 hospitals in 31 provinces/provincial municipalities through January 29th, 2020. Results The median age was 47.0 years, and 41.90% were females. Only 1.18% of patients had a direct contact with wildlife, whereas 31.30% had been to Wuhan and 71.80% had contacted with people from Wuhan. Fever (87.9%) and cough (67.7%) were the most common symptoms. Diarrhea is uncommon. The median incubation period was 3.0 days (range, 0 to 24.0 days). On admission, ground-glass opacity was the typical radiological finding on chest computed tomography (50.00%). Significantly more severe cases were diagnosed by symptoms plus reverse-transcriptase polymerase-chain-reaction without abnormal radiological findings than non-severe cases (23.87% vs. 5.20%, P Conclusions The 2019-nCoV epidemic spreads rapidly by human-to-human transmission. Normal radiologic findings are present among some patients with 2019-nCoV infection. The disease severity (including oxygen saturation, respiratory rate, blood leukocyte/lymphocyte count and chest X-ray/CT manifestations) predict poor clinical outcomes.
1,358 citations
••
TL;DR: The humoral response to SARS-CoV-2 can aid in the diagnosis of COVID-19, including subclinical cases, and the detection efficiency by IgM ELISA is higher than that of qPCR after 5.5 days of symptom onset.
Abstract: Background The emergence of coronavirus disease 2019 (COVID-19) is a major healthcare threat. The current method of detection involves a quantitative polymerase chain reaction (qPCR)-based technique, which identifies the viral nucleic acids when present in sufficient quantity. False-negative results can be achieved and failure to quarantine the infected patient would be a major setback in containing the viral transmission. We aim to describe the time kinetics of various antibodies produced against the 2019 novel coronavirus (SARS-CoV-2) and evaluate the potential of antibody testing to diagnose COVID-19. Methods The host humoral response against SARS-CoV-2, including IgA, IgM, and IgG response, was examined by using an ELISA-based assay on the recombinant viral nucleocapsid protein. 208 plasma samples were collected from 82 confirmed and 58 probable cases (qPCR negative but with typical manifestation). The diagnostic value of IgM was evaluated in this cohort. Results The median duration of IgM and IgA antibody detection was 5 (IQR, 3-6) days, while IgG was detected 14 (IQR, 10-18) days after symptom onset, with a positive rate of 85.4%, 92.7%, and 77.9%, respectively. In confirmed and probable cases, the positive rates of IgM antibodies were 75.6% and 93.1%, respectively. The detection efficiency by IgM ELISA is higher than that of qPCR after 5.5 days of symptom onset. The positive detection rate is significantly increased (98.6%) when combining IgM ELISA assay with PCR for each patient compared with a single qPCR test (51.9%). Conclusions The humoral response to SARS-CoV-2 can aid in the diagnosis of COVID-19, including subclinical cases.
1,350 citations
••
TL;DR: Non-inferior survival of gefitinib compared with docetaxel is established, suggesting that gef itinib is a valid treatment for pretreated patients with advanced non-small-cell lung cancer.
1,231 citations
••
TL;DR: Streamlining of workflows for rapid diagnosis and isolation, clinical management, and infection prevention will matter not only to patients with COVID-19, but also to health-care workers and other patients who are at risk from nosocomial transmission.
1,147 citations
Authors
Showing all 16286 results
Name | H-index | Papers | Citations |
---|---|---|---|
Feng Zhang | 172 | 1278 | 181865 |
Jian Li | 133 | 2863 | 87131 |
Shuai Liu | 129 | 1095 | 80823 |
Jun Yu | 121 | 1174 | 81186 |
Edward M. Brown | 111 | 489 | 44630 |
Qian Wang | 108 | 2148 | 65557 |
Ming Li | 103 | 1669 | 62672 |
Tao Li | 102 | 2483 | 60947 |
Masatoshi Kudo | 100 | 1324 | 53482 |
Christophe Tzourio | 98 | 475 | 53680 |
Yang Xin Fu | 97 | 390 | 33526 |
Michael Q. Zhang | 93 | 378 | 42008 |
Xiang Gao | 92 | 1359 | 42047 |
Jun Li | 90 | 339 | 61485 |
Honglei Chen | 80 | 207 | 83906 |